XML 29 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue from Contract with Customer
 12 Months Ended
Jan. 02, 2022
Revenue from Contract with Customer [Abstract]  
Revenue from Contract with Customer [Text Block] RevenueFor arrangements with multiple performance obligations, the Company accounts for individual products and services separately if they are distinct - i.e. if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The consideration (including any discounts) is allocated between separate products and services in a bundle based on their stand-alone selling prices. The stand-alone selling prices are determined based on the prices at which the Company separately sells the products,
extended warranties, and services. For items that are not sold separately, the Company estimates stand-alone selling prices by reference to the amount charged for similar items on a stand-alone basis.
The Company sells products and services predominantly through its direct sales force. As a result, the use of distributors is generally limited to geographic regions where the Company has no direct sales force. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including distributors. Payment terms granted to distributors are the same as those granted to end-customers and payments are not dependent upon the distributor's receipt of payment from their end-user customers.
In instances where the timing of revenue recognition differs from the timing of invoicing, the Company determined that the contracts generally do not include a significant financing component. The primary purpose of its invoicing terms is to provide customers with simplified and predictable ways of purchasing products and services, rather than to receive financing from the customers or to provide customers with financing. Examples include invoicing at the beginning of a subscription term with revenue recognized ratably over the contract period, and multi-year software licenses or software subscriptions that are invoiced annually with revenue recognized upfront. In limited circumstances where the Company provides the customer with a significant benefit of financing, the Company uses the practical expedient and only adjusts the transaction price for the effects of the time value of money and only on contracts where the duration of financing is more than one year.
Nature of goods and services
The Discovery & Analytical Solutions segment of the Company principally generates revenue from sales of (a) instruments, consumables and services in the applied markets and (b) instruments, reagents, informatics, software, subscriptions, detection and imaging technologies, extended warranties, training and services in the life sciences market. The Diagnostics segment of the Company principally generates revenue from sales of instruments, solutions, consumables, reagents, extended warranties and services in the diagnostics market. Products and services may be sold separately or in bundled packages. The typical length of a contract for service is 12 to 36 months.
The revenue generated from the sale of instruments, consumables, reagents, and certain software is recognized at a point in time. The Company recognizes revenue in these arrangements at the point in time when control of the products has been transferred to customers, which is typically at delivery. Certain of the Company's products require specialized installation and configuration at the customer's site. Revenue for these products is deferred until installation is complete and customer acceptance has been received. When the Company places the instrument at the customer's site and sells the reagents to a customer, the instrument and reagents are accounted for together as one performance obligation. The Company does not charge a fee for the use of the instrument and retains ownership of the placed instrument. The Company has a right to remove the instrument and replace it with another instrument at the customer's site at any time throughout the contract term. The Company recognizes revenue upon delivery of reagents, which is the point in time where the Company has performed its obligation to provide a screening solution to the customer. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 to 60 days.
The revenue generated from the sale of licenses for software as a service, cloud services, subscriptions, extended warranties, and laboratory services and training is recognized over time. Term licenses, subscriptions and cloud services, are generally recognized ratably over the contract period or based upon consumption. The Company sells its software subscriptions and cloud services with maintenance services and, in some cases, with consulting services. The Company recognizes revenue for the software commencing when the service is made available to the customer. For maintenance and consulting services, revenue is recognized ratably over the period in which the services are provided. Revenue for laboratory services is recognized over the contract period or at a point in time when the service is billable, based on time and materials. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 to 60 days.
Disaggregation of revenue
In the following tables, revenue is disaggregated by primary geographical market, end-markets and timing of revenue recognition.
Reportable Segments
For the fiscal year ended
January 2, 2022January 3, 2021December 29, 2019
Discovery & Analytical SolutionsDiagnosticsTotalDiscovery & Analytical SolutionsDiagnosticsTotalDiscovery & Analytical SolutionsDiagnosticsTotal
(In thousands)
Primary geographical markets
Americas$876,367 $1,362,213 $2,238,580 $695,960 $750,641 $1,446,601 $717,205 $401,591 $1,118,796 
Europe599,886 982,476 1,582,362 490,789 864,687 1,355,476 495,768 291,610 $787,378 
Asia658,977 587,250 1,246,227 529,054 451,614 980,668 533,188 444,311 $977,499 
$2,135,230 $2,931,939 $5,067,169 $1,715,803 $2,066,942 $3,782,745 $1,746,161 $1,137,512 $2,883,673 
Primary end-markets
Diagnostics$— $2,931,939 $2,931,939 $— $2,066,942 $2,066,942 $— $1,137,512 $1,137,512 
Life sciences1,337,340 — 1,337,340 1,032,209 — 1,032,209 977,200 — $977,200 
Applied markets797,890 — 797,890 683,594 — 683,594 768,961 — $768,961 
$2,135,230 $2,931,939 $5,067,169 $1,715,803 $2,066,942 $3,782,745 $1,746,161 $1,137,512 $2,883,673 
Timing of revenue recognition
Products and services transferred at a point in time$1,595,245 $2,285,836 $3,881,081 $1,195,249 $1,891,482 $3,086,731 $1,276,499 $1,053,974 $2,330,473 
Services transferred over time539,985 646,103 1,186,088 520,554 175,460 696,014 469,662 83,538 553,200 
$2,135,230 $2,931,939 $5,067,169 $1,715,803 $2,066,942 $3,782,745 $1,746,161 $1,137,512 $2,883,673 

Major Customer Concentration
Revenues from one customer in the Company's Diagnostics segment represent approximately $638.6 million, $97.8 million and $30.8 million of the Company's total revenue during the fiscal years 2021, 2020 and 2019, respectively.
Contract Balances
Contract assets: The unbilled receivables (contract assets) primarily relate to the Company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are transferred to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in "Accounts receivable, net" in the consolidated balance sheets.

 (In thousands)
Balance at December 29, 2019$37,036 
Transferred to trade receivables from unbilled receivables recognized at the beginning of the period(33,236)
Increases as a result of recognition of revenue before billing to customers, excluding amounts transferred to trade receivables during the period55,674 
Balance at January 3, 202159,474 
Transferred to trade receivables from unbilled receivables recognized at the beginning of the period(51,969)
Increases as a result of recognition of revenue before billing to customers, excluding amounts transferred to trade receivables during the period64,612 
Balance at January 2, 2022$72,117 
Contract liabilities: The contract liabilities primarily relate to the advance consideration received from customers for products and related installation for which transfer of control has not occurred at the balance sheet date. Contract liabilities are classified as either current in "Accounts payable" or "Accrued expenses and other current liabilities" or as long-term in "Long-term liabilities" in the consolidated balance sheets based on the timing of when the Company expects to recognize revenue.
 (In thousands)
Balance at December 29, 2019$29,944 
Revenue recognized that was included in the contract liability balance at the beginning of the period(27,328)
Increases due to cash received, excluding amounts recognized as revenue during the period235,499 
Balance at January 3, 2021238,115 
Revenue recognized that was included in the contract liability balance at the beginning of the period(99,997)
Increases due to cash received, excluding amounts recognized as revenue during the period62,955 
Balance at January 2, 2022$201,073 
Contract costs: The Company recognizes the incremental costs of obtaining a contract with a customer as an asset if it expects the benefit of those costs to be longer than one year. The Company determined that certain sales incentive programs meet the requirements to be capitalized. Total capitalized costs to obtain a contract were immaterial during the period and are included in other current and long-term assets on the consolidated balance sheets. The Company applies a practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less.
Transaction price allocated to the remaining performance obligations
The Company applies the practical expedient in ASC 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The estimated revenue expected to be recognized beyond one year in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the period are not material to the Company. The remaining performance obligations primarily include noncancelable purchase orders and noncancelable software subscriptions and cloud service contracts.